** Shares of Gyre Therapeutics GYRE.O down 15.3% before the bell to $9.50 after follow-on priced
** San Diego-based biotech late Thurs announced ~2.2 mln shares at $9 for $20 mln gross proceeds
** Offering price represents 19.7% discount to stock's last sale
** Co intends to use net proceeds to fund advancement of its Phase II trial of F351 in metabolic dysfunction-associated steatohepatitis ("MASH”)-associated liver fibrosis in the U.S., for R&D, and manufacturing among other purposes
** Jefferies is bookrunner for offering
** Late Thurs, co said its lead compound, Hydronidone (F351), met primary endpoint in pivotal Phase III trial evaluating efficacy and safety for treatment of fibrosis in patients with chronic hepatitis B in China
** With ~93.8 mln shares outstanding as of May 1, co has ~$1bln market cap
** GYRE shares on Thurs rose 8.1% to $11.21, trimming YTD loss to ~7%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.